The Application Notebook
Opiate abuse is drastically on the rise in the United States. In addition to traditional naturally occurring opiate compounds, forensic toxicologists also need to be able to rapidly identify synthetic opioid-like drugs. A rapid, three-step solid-phase extraction (SPE) procedure for the identification and quantification of fentanyl and its major urinary metabolite norfentanyl, in addition to four “designer” compounds, U-47700, W-18, W-15, and furanyl fentanyl, is presented here. As a result of the rapid use and abuse of fentanyl in medical and recreational settings, respectively, it is important to develop a method that can accurately extract this Schedule II drug from any other novel compounds that may be present.
Danielle Mackowsky, UCT, LLC
Summary
Opiate abuse is drastically on the rise in the United States. In addition to traditional naturally occurring opiate compounds, forensic toxicologists also need to be able to rapidly identify synthetic opioid-like drugs. A rapid, three-step solid-phase extraction (SPE) procedure for the identification and quantification of fentanyl and its major urinary metabolite norfentanyl, in addition to four “designer” compounds, U-47700, W-18, W-15, and furanyl fentanyl, is presented here. As a result of the rapid use and abuse of fentanyl in medical and recreational settings, respectively, it is important to develop a method that can accurately extract this Schedule II drug from any other novel compounds that may be present.
Procedure
1. Sample Pretreatment:
To 1 mL of urine sample, add 1 mL of 100 mM phosphate buffer (pH = 6) and an appropriate amount of internal standard.
2. Sample Extraction:
Apply the sample to the SPE cartridge (if required, use a low vacuum to draw the sample through at ≤3 mL/min).
3. Wash Cartridge:
a) 1 × 3 mL D.I. H2O
b) 1 × 3 mL 100 mM acetic acid
c) Dry column under full vacuum or pressure for 10 min.
4. Elution:
a) 1 × 3 mL methanol containing 2% ammonium hydroxide (methanol:NH4OH, 98:2 v/v).
b) Evaporate the sample to dryness under a gentle stream of nitrogen.
c) Reconstitute in 100 µL 95:5 D.I. H2O:methanol and vortex for 1 min.
d) Transfer sample to autosampler vial containing a low volume insert.
Instrumental
LC–MS/MS: Thermo Scientific™ Dionex™ Ultimate™ 3000 UHPLC and TSQ Vantage™ (MS/MS)
Column: 100 × 2.1 mm, 3-μm UCT Selectra® DA HPLC column
Guard Column: 10 × 2.1 mm, 3-μm UCT Selectra® DA guard column
Injection Volume: 5 μL
Mobile Phase A: D.I. H2O 0.1% formic acid
Mobile Phase B: Methanol 0.1% formic acid
Column Flow Rate: 0.30 mL/min
Results
Conclusion
A fast and effective method was developed for the determination of six designer opiates in urine samples. All analytes of interest were extracted using a Clean Screen® XCEL I column. Analysis of the samples was performed by LC–MS/MS utilizing a Selectra® DA HPLC column, which allowed for improved separation of furanyl fentanyl and fentanyl, when compared to other column phases. Absolute recoveries ranged from 72.9–125.3% for all three control levels tested. With the unfortunate (and often unaware) abuse of synthetic opiates throughout the United States, it is critical that forensic laboratories have accurate and rapid SPE methods for the identification of this class of compounds. This method will be of great use as drugs with similar structures start to be found in casework.
UCT, LLC
2731 Bartram Road, Bristol, Pennsylvania 19007, USA
Tel: (800) 385 3153
E-mail: methods@unitedchem.com Website: www.unitedchem.com
Modern HPLC Strategies: Improving Retention and Peak Shape for Basic Analytes
August 16th 2024In high-performance liquid chromatography (HPLC), it is common for bases and unreacted ionized silanols on silica-based columns to cause irreproducible retention, broad peaks, and peak tailing when working with basic analytes. David S. Bell, Lead Consultant at ASKkPrime LLC offers innovative HPLC strategies that can help mitigate such issues.
Reliable and Objective Antibody Analysis with the New Agilent ProteoAnalyzer System
September 18th 2024This technical overview compares the characterization of NISTmAb using the ProteoAnalyzer with published NIST data obtained via traditional single capillary CE-SDS technology. The results show strong correlation with the reference data, confirming that the ProteoAnalyzer is a reliable tool for analytical workflows.